Newsroom | 83787 results

DUBLIN--(BUSINESS WIRE)--The "Hydrastine (CAS 118-08-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Hydrastine provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understa...

DUBLIN--(BUSINESS WIRE)--The "Deferiprone (CAS 30652-11-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Deferiprone provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for unde...

DUBLIN--(BUSINESS WIRE)--The "Clonidine (CAS 4205-90-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Clonidine provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understan...

ABU DHABI, Emirati Arabi Uniti--(BUSINESS WIRE)--Abu Dhabi ha lanciato l'innovativo cluster dedicato al settore delle scienze della vita, rafforzando la sua posizione di hub globale per la biotecnologia, la tecnologia medica e la sanità digitale. Sviluppato dal Dipartimento per lo Sviluppo Economico di Abu Dhabi, dall'Ufficio per gli Investimenti di Abu Dhabi (ADIO) e dal Dipartimento della Salute di Abu Dhabi, il cluster HELM (Health, Endurance, Longevity, and Medicine) è stato progettato per...

ABU DHABI, Verenigde Arabische Emiraten--(BUSINESS WIRE)--Abu Dhabi heeft het baanbrekende life sciences-cluster gelanceerd, waardoor de positie van het land als een wereldwijde hub voor biotechnologie, MedTech en digitale gezondheid wordt versterkt. Het Health, Endurance, Longevity and Medicine (HELM)-cluster is ontwikkeld door het Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) en het Department of Health – Abu Dhabi, en is ontworpen om innovatie in de gezondh...

DUBLIN--(BUSINESS WIRE)--The "Oxycodone (CAS 76-42-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. This report on Oxycodone provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understandi...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France....

東京--(BUSINESS WIRE)--(美國商業資訊)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（總部：東京昭島市；執行長：Jun Kawakami；以下簡稱「Rigaku」），與SPERA PHARMA, Inc.（總部：大阪市；董事長兼代表董事：Keitaro Iwaki；以下簡稱「SPERA PHARMA」）宣佈達成戰略合作，旨在通過整合雙方尖端技術與深厚專業知識，加速並革新藥物研發進程。 SPERA PHARMA將採用Rigaku提供的電子衍射集成平台XtaLAB Synergy-ED開展合約分析服務，為客戶的藥物研發提供強力支援。 XtaLAB Synergy-ED搭載的3D ED/MicroED1可用於物質結構分析，包括顯微晶體和微量結晶粉末。這項尖端技術具有足夠高的解析度，可以確定原子級結構，從而詳細闡明有機化合物及類似物質的分子結構。 SPERA PHARMA目前是全球醫藥行業唯一一家提供XtaLAB Synergy-ED合約分析服務的企業。Rigaku將為SPERA PHARMA的合約分析業務提供全面...

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications...

东京--(BUSINESS WIRE)--(美国商业资讯)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（总部：东京昭岛市；首席执行官：Jun Kawakami；以下简称“Rigaku”），与SPERA PHARMA, Inc.（总部：大阪市；董事长兼代表董事：Keitaro Iwaki；以下简称“SPERA PHARMA”）宣布达成战略合作，旨在通过整合双方尖端技术与深厚专业知识，加速并革新药物研发进程。 SPERA PHARMA将采用Rigaku提供的电子衍射集成平台XtaLAB Synergy-ED开展合约分析服务，为客户的药物研发提供强力支持。 XtaLAB Synergy-ED搭载的3D ED/MicroED1可用于物质结构分析，包括显微晶体和微量结晶粉末。这项尖端技术具有足够高的分辨率，可以确定原子级结构，实现有机化合物和类似物质分子结构的精密阐明。 SPERA PHARMA目前是全球医药行业唯一一家提供XtaLAB Synergy-ED合约分析服务的企业。Rigaku将为SPERA PHARMA的合约分析业务提供...